Abstract
Mycobacterial infections, caused by bacteria such as Mycobacterium tuberculosis (Mtb) and nontuberculous mycobacteria (NTM), are among the most widespread infectious diseases worldwide. The latest WHO report again ranks Mtb among the most dangerous pathogens. NTM lung infections are rising, especially in developed countries, now surpassing TB in incidence. These infections are particularly severe in patients with conditions like cystic fibrosis or COPD, where a lack of effective treatment can be fatal.
We aim to explore the feasibility of establishing a program that meets the demands of modern antimycobacterial drug discovery. This initiative would adopt a promising yet underexplored strategy, integrating cutting-edge chemical, biological, and computational technologies through an interdisciplinary approach to identify novel targets and develop selective inhibitors.
Researcher(s)
Research team(s)
Project type(s)